ResearchSafe

AOD-9604 (Advanced Obesity Drug Fragment 176-191 (Modified))

Category: Weight Management. Status: Research compound.

A modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis and inhibits lipogenesis. Originally developed as an anti-obesity drug with no effect on IGF-1 or blood glucose.

How it works

Mimics the lipolytic domain of growth hormone (hGH 176-191), stimulating fat oxidation and inhibiting de novo lipogenesis through pathways independent of IGF-1 and growth signaling.

Key facts

  • Molecular weight: 1815.08 Da
  • Half-life: ~2-3 hours
  • Bioavailability: ~90% subcutaneous
  • Storage: Lyophilized: 2-8°C. Reconstituted: 2-8°C for up to 30 days.

Dosing overview

  • Typical dose: 300 mcg
  • Frequency: Daily (morning, fasted)
  • Duration: 12 weeks
  • Route: Subcutaneous injection

Protocol notes

  • Most run ~300 mcg once daily, injected subcutaneously in the morning on an empty stomach.
  • Some split into 2x150 mcg (AM and pre-workout) to align with fasted/active windows.
  • Often stacked with a GH secretagogue (CJC-1295/Ipamorelin) since AOD-9604 itself does not raise IGF-1.

Reported benefits

  • Fat loss without muscle wasting
  • No effect on blood sugar
  • Cartilage repair properties
  • No HGH-related side effects

Possible side effects

  • Injection site soreness
  • Headache
  • Mild stomach discomfort

Research

  • AOD-9604 lipolytic effects in obese subjects (2019): Demonstrated significant fat mass reduction without changes in IGF-1 or glucose tolerance.
  • HGH fragment 176-191 cartilage regeneration (2020): Showed chondroprotective effects and stimulated proteoglycan synthesis in osteoarthritic cartilage.

Compare AOD-9604

Community discussions about AOD-9604

Research and educational reference only. Not medical advice.